AZN News and Press, AstraZeneca PLC From 07/02/24

2024-07-02 09:17:30 ET More on Eli Lilly 5 Reasons Eli Lilly Just Keeps Rising Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis) Eli Lilly: The Party Is Probably Nearing The End Lilly in deal with Radionetics Oncology on radiopha...

2024-07-02 08:30:07 ET Jefferies analyst issues HOLD recommendation for AZN on July 2, 2024 06:20AM ET. The previous analyst recommendation was Hold. AZN was trading at $77.94 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...

2024-07-01 06:28:32 ET AstraZeneca ( NASDAQ: AZN ) said Monday its marketing authorization application for its investigational COVID-19 prevention drug, sipavibart, has been accepted for an accelerated assessment by the EU drug regulator.... Read the full article on Seeking Al...

2024-06-30 20:30:56 ET Rounding out the top five were Moderna ( NASDAQ: MRNA ) and Novo Nordisk ( NVO ) with gains of, respectively, ~12.5% and ~11.9% .... Read the full article on Seeking Alpha For further details see: Alnylam, Lilly, AstraZeneca among best ...

2024-06-30 09:25:12 ET Summary Mereo BioPharma Group plc has seen a rebound in its stock over the past year, with positive analyst commentary in the second quarter. The company is focused on developing therapeutics for oncology and rare diseases, with a lead candidate for Osteogen...

2024-06-29 22:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-29 15:44:55 ET More on Eli Lilly, Novo Nordisk, etc. Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis) Eli Lilly: The Party Is Probably Nearing The End ...

2024-06-26 08:02:00 ET More on AstraZeneca AstraZeneca's Oncology Success: Fueling Future Growth AstraZeneca: The Price Upside Is Exhausted For Now (Rating Downgrade) AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZenec...

2024-06-25 12:54:41 ET Summary AstraZeneca is becoming a leader in the cancer therapeutics market, which is reflected in the growth of its share price. On June 25, 2024, Tagrisso, in combination with chemotherapy, was approved in Japan as the first-line treatment for people with N...

2024-06-25 10:24:44 ET More on AstraZeneca AstraZeneca: The Price Upside Is Exhausted For Now (Rating Downgrade) AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZen...